Dogwood Therapeutics
DWTX
23 hedge funds and large institutions have $766K invested in Dogwood Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 3 closing their positions.
0% more ownership
Funds ownership: 0.17% → 0.17% (+0%)
4% less funds holding
Funds holding: 24 → 23 (-1)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
29% less capital invested
Capital invested by funds: $1.08M → $766K (-$312K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$70K |
| 2 |
VF
Virtu Financial
New York
|
+$38K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$37.8K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$31.4K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$12.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$46K |
| 2 |
Renaissance Technologies
New York
|
-$45.1K |
| 3 |
Belvedere Trading
Chicago,
Illinois
|
-$25K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$7.16K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$7.09K |
DWTX Hedge Fund Activity: Q3 2023 in Review
23 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Dogwood Therapeutics (DWTX) for Q3 2023, worth a combined $766K — down 29% from $1.08M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of DWTX and 2 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 5 added.
The largest buyer was Susquehanna International Group, adding an estimated $70K. The largest seller was Citadel Advisors, exiting entirely with an estimated $46K sold.
- 23 institutional investors held Dogwood Therapeutics (DWTX) as of Q3 2023, down from 24 in Q2 2023.
- Funds reported $766K of Dogwood Therapeutics stock for Q3 2023, down 29% quarter-over-quarter.
- 2 funds opened new Dogwood Therapeutics positions in Q3 2023 and 3 closed out, a net change of -1 holder.
- The largest Dogwood Therapeutics buyer in Q3 2023 was Susquehanna International Group, an estimated $70K added.
- The largest Dogwood Therapeutics seller in Q3 2023 was Citadel Advisors, an estimated $46K sold.
Based on aggregated 13F filings for Q3 2023.